Pharma Intelligence is part of the Business Intelligence Division of Informa PLC

TThis is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Informa
alt text

The concept of Developability underpins all aspects of antibody discovery, lead selection and lead optimisation. Developability at Abzena is addressed in the context of Specificity & Functionality, Immunogenicity & Safety and Manufacturability with additional considerations for ADCs and other bioconjugates.

Why assess Developability?

  • Allows the identification of risk factors early in the development process
  • Provides scope to apply design alterations to fix/reduce liabilities, or to develop strategies to manage liabilities
  • Reduces the likelihood of major issues arising at a later, more costly, stage of development
  • Ensures the selection of the best drug candidate(s) for development

Abzena combines Developability and Rational Design through the application of a series of stage appropriate in silico, in vitro and ex vivo experiments which have been designed to characterize and select a lead drug candidate with the greatest chance of clinical success.

Speaker

alt text

Dr Mark Frigerio

VP of Design & Developability

Abzena

Mark has over 15 years of drug development experience in various roles including at Abzena, KuDOS Pharmaceuticals and Pharminox. He is an expert in the design and development of linkers that have applications in bioconjugation, particularly in the field of Antibody Drug Conjugates (ADC) and have been instrumental in building Abzena’s site-specific ThioBridge® conjugation technology platform for the production of stable and homogeneous ADCs. He currently runs the Abzena Chemistry, design and development groups in the UK.

Hosted by

Maire Gerrard

Custom Content Writer

Informa Pharma Intelligence

Complete the form to register your free place!

By ticking this box, you agree to receive emails such as relevant news, updates and offers from Informa Business Intelligence, and carefully selected similar products from our portfolio
By ticking this box, you agree to receive emails such as promotional offers from other members of the Informa group and selected 3rd party companies

By completing this form you agree Abzena may contact you directly about industry news, products, services and events that may be of interest to you subject to their privacy policy.